27.32
price down icon2.57%   -0.72
after-market アフターアワーズ: 27.32
loading
前日終値:
$28.04
開ける:
$28.03
24時間の取引高:
301.07K
Relative Volume:
0.47
時価総額:
$1.74B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.4049
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-9.24%
1か月 パフォーマンス:
+3.96%
6か月 パフォーマンス:
-53.74%
1年 パフォーマンス:
-17.01%
1日の値動き範囲:
Value
$27.27
$28.91
1週間の範囲:
Value
$27.27
$30.50
52週間の値動き範囲:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1153)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
488
Name
Twitter
@AgiosPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

AGIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
27.32 1.74B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
07:21 AM

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus

07:21 AM
pulisher
07:19 AM

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times

07:19 AM
pulisher
May 08, 2025

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire

May 08, 2025
pulisher
May 07, 2025

Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com

May 07, 2025
pulisher
May 03, 2025

Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN

May 03, 2025
pulisher
May 03, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus

May 03, 2025
pulisher
May 02, 2025

Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK

May 02, 2025
pulisher
May 02, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times

May 02, 2025
pulisher
May 02, 2025

Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha

May 02, 2025
pulisher
May 01, 2025

Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com

May 01, 2025
pulisher
May 01, 2025

Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com

May 01, 2025
pulisher
May 01, 2025

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA

May 01, 2025
pulisher
May 01, 2025

Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com

May 01, 2025
pulisher
Apr 30, 2025

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN

Apr 30, 2025
pulisher
Apr 30, 2025

An Overview of Agios Pharmaceuticals's Earnings - Nasdaq

Apr 30, 2025
pulisher
Apr 29, 2025

Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com

Apr 29, 2025
pulisher
Apr 24, 2025

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN

Apr 24, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times

Apr 17, 2025
pulisher
Apr 14, 2025

Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com

Apr 14, 2025
pulisher
Apr 12, 2025

Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 10, 2025

Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView

Apr 10, 2025
pulisher
Apr 08, 2025

Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 04, 2025

RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail

Apr 04, 2025
pulisher
Apr 03, 2025

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

New Strong Sell Stocks for April 3rd - TradingView

Apr 03, 2025
pulisher
Apr 01, 2025

Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Agios stock touches 52-week low at $27.12 amid market shifts By Investing.com - Investing.com South Africa

Apr 01, 2025

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
大文字化:     |  ボリューム (24 時間):